b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">29251018</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>04</Month>\n            <Day>18</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>12</Month>\n            <Day>02</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1744-7666</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>19</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>Feb</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Expert opinion on pharmacotherapy</Title>\n                <ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Cardiovascular outcomes with canagliflozin - is it on the CANVAS?</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>163-166</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1080/14656566.2017.1418855</ELocationID>\n            <Abstract>\n                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Sodium-glucose cotransporter 2 (SGLT2) inhibitors (the \'gliflozins\') promote the excretion of glucose from the kidney to lower HbA1c. Empagliflozin was the first gliflozin shown to improve cardiovascular and renal outcomes in subjects with type 2 diabetes and cardiovascular disease. Areas covered: In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, there were improvements in the primary cardiovascular and exploratory renal outcomes with canagliflozin, compared to placebo. The safety outcome finding, which was of most interest, was that there was a higher risk of amputation of toes, feet, or legs with canagliflozin than in the placebo group. This program is the subject of this evaluation. Expert opinion: As canagliflozin has small beneficial effects in the treatment of type 2 diabetes in subjects with cardiovascular disease, it is not on the canvas. However, there are still several questions about canagliflozin that need to be answered before it is widely used, especially in comparison with other gliflozins; As amputations have only been reported with canagliflozin in CANVAS, should other gliflozins be preferred? As canagliflozin has not been shown to be beneficial in subjects not taking diuretics, should other gliflozins be preferred in this population? Clarification is also needed as to whether canagliflozin increases the risk of non-fatal stroke, or not.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Doggrell</LastName>\n                    <ForeName>Sheila A</ForeName>\n                    <Initials>SA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Faculty of Health , Queensland University of Technology , Brisbane , Australia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016430">Clinical Trial</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>12</Month>\n                <Day>22</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Expert Opin Pharmacother</MedlineTA>\n            <NlmUniqueID>100897346</NlmUniqueID>\n            <ISSNLinking>1465-6566</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C089180">SLC5A2 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D051297">Sodium-Glucose Transporter 2</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C517652">hemoglobin A1c protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0SAC974Z85</RegistryNumber>\n                <NameOfSubstance UI="D000068896">Canagliflozin</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000068896" MajorTopicYN="N">Canagliflozin</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>\n                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin A</DescriptorName>\n                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName>\n                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015990" MajorTopicYN="N">Placebo Effect</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051297" MajorTopicYN="N">Sodium-Glucose Transporter 2</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077203" MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Canagliflozin</Keyword>\n            <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>\n            <Keyword MajorTopicYN="N">cardiovascular outcomes</Keyword>\n            <Keyword MajorTopicYN="N">dapagliflozin</Keyword>\n            <Keyword MajorTopicYN="N">empagliflozin</Keyword>\n            <Keyword MajorTopicYN="N">gliflozins</Keyword>\n            <Keyword MajorTopicYN="N">renal outcomes</Keyword>\n            <Keyword MajorTopicYN="N">type 2 diabetes</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>12</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>4</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>12</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29251018</ArticleId>\n            <ArticleId IdType="doi">10.1080/14656566.2017.1418855</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'